Cognify was advertised by CellMark Biopharma, LLC as “the world’s first product designed specifically to alleviate chemo brain (chemo fog) signs and symptoms.” They also say it “increases cognitive processing” and that it can “Repair Brain Tissue.”
According to the FTC, there were no human clinical studies of either CellAssure or Cognify to prove their respective claims. They’ve not been tested to show whether they help with cancer-related malnutrition or helping chemo patients.
Because of the claims made by CellMark Biopharma, the FTC sued because they believe that if CellMark Biopharma had been left unchecked, they would have continued to hurt consumers and harm public interest. In paragraph 28, the FTC stated that if the Court would not intervene, the defendant would have continued to “reap unjust enrichment.” In plain English, the FTC didn’t want this company to continue to take money from cancer patients and their families by convincing them their product was clinically proven to work.
